Differential diagnosis of focal liver lesions: role of spin-echo and contrast-enhanced dynamic MR imaging

LI-RADS technical requirements for CT, MRI, and contrast-enhanced ultrasound

Accurate detection and characterization of liver observations to enable HCC diagnosis and staging using LI-RADS requires a technically adequate imaging exam. To help achieve this objective, LI-RADS has proposed technical requirements for CT, MR, and contrast-enhanced ultrasound of liver. This article reviews the technical requirements for liver imaging, including the description of minimum acceptable technical standards, such as the scanner hardware requirements, recommended dynamic imaging phases, and common technical challenges of liver imaging.

Liver-Directed Radiotherapy for Hepatocellular Carcinoma

BACKGROUND

The incidence of hepatocellular carcinoma (HCC) continues to increase world-wide. Many patients present with advanced disease with extensive local tumor or vascular invasion and are not candidates for traditionally curative therapies such as orthotopic liver transplantation (OLT) or resection. Radiotherapy (RT) was historically limited by its inability to deliver a tumoricidal dose; however, modern RT techniques have prompted renewed interest in the use of liver-directed RT to treat patients with primary hepatic malignancies.

SUMMARY

The aim of this review was to discuss the use of external beam RT in the treatment of HCC, with particular focus on the use of stereotactic body radiotherapy (SBRT). We review the intricacies of SBRT treatment planning and delivery. Liver-directed RT involves accurate target identification, precise and reproducible patient immobilization, and assessment of target and organ motion. We also summarize the published data on liver-directed RT, and demonstrate that it is associated with excellent local control and survival rates, particularly in patients who are not candidates for OLT or resection.

KEY MESSAGES

Modern liver-directed RT is safe and effective for the treatment of HCC, particularly in patients who are not candidates for OLT or resection. Liver-directed RT, including SBRT, depends on accurate target identification, precise and reproducible patient immobilization, and assessment of target and organ motion. Further prospective studies are needed to fully delineate the role of liver-directed RT in the treatment of HCC.

Impact of intravenous contrast enhancement phase on target definition for hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (IHC): Observations from patients enrolled on a prospective phase 2 trial

BACKGROUND

The safety and efficacy of radiation therapy for hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (IHC) depend on accurate definition of gross tumor volume (GTV), but GTV often varies between phases of multiphasic computed tomography (CT) imaging.

METHODS

We contoured GTVs on arterial, portal venous, and delayed phases of multiphasic CT scans for 32 patients treated on an institutional review board-approved prospective trial of proton therapy for primary liver tumors and determined which phase provided optimal GTV visualization. We assessed agreement between individual phase GTVs to determine if GTV for each phase was encompassed in a 5-mm expansion of either the smallest or the best-visualized GTV.

RESULTS

There were 19 HCC lesions and 14 IHC lesions. HCC lesions were best identified on the arterial phase in 42% (n = 8), portal venous phase in 32% (n = 6), and delayed phase in 26% (n = 5). IHC lesions were best identified on portal venous phase in 64% (n = 9) and the arterial phase in 29% (n = 4), with 1 case equally visualized on arterial and portal venous phases. In all 33 lesions, a 5-mm expansion around the smallest GTV failed to cover GTVs defined on other available phases. A 5-mm expansion around the best-visualized GTV provided satisfactory coverage of all available phases' GTVs in 6/18 HCC cases and 2/9 IHC cases.

CONCLUSIONS

Variability between GTVs on multiphasic CT scans could not be overcome with a 5-mm expansion of either the smallest GTV or the best-visualized GTV. Assessment of all available intravenous contrast phases is essential to accurately define the GTV.

Benign liver lesions: grey-scale and contrast-enhanced ultrasound appearances

Ultrasound is often the first point of detection of liver lesions, with up to 75% of liver lesions detected at ultrasound having benign histology. In 2012, NICE issued recommendations that ultrasound contrast be used for the evaluation of incidentally discovered liver lesions. This has been demonstrated to provide a rapid and cost-effective evaluation for incidental liver lesions, in many cases precluding the need for further CT or MRI scans. The aim of this review is to demonstrate the ultrasound features of benign liver lesions, and to demonstrate their further characterisation with contrast ultrasound.

Let's go out of the breast: prevalence of extra-mammary findings and their characterization on breast MRI

PURPOSE

The aim of this study is to assess the prevalence, the site and the nature of extra-mammary findings on breast magnetic resonance imaging (MRI) and to determine its accuracy in the characterization of the discovered lesions.

MATERIALS AND METHODS

A retrospective review of 308 female patients (mean age 50 ± 20) who underwent breast MRI with 1.5T device was performed. 125 out of 308 (40.5%) had a positive personal history of breast cancer (pre-operative n=80; follow-up n=45), while the remaining 183 without history of breast cancer (high familiar risk for breast cancer n=80; dense breast n=103). All incidental findings were characterized by means of additional imaging (US; Bone scintigraphy-MRI; CT-PET-CT).

RESULTS

59 incidental findings were found in 53/308 (17%) examined patients. 9/59 incidental findings (15%) were confirmed to be malignant while the remaining 50/59 (84%) benign. The most common site was the liver (33/59; 55.8%), followed by the lung (6/59; 10.1%), bone (6/59; 10.1%), diaphragm (6/59; 10.1%) spleen (3/59; 5%), kidney (2/59; 3.4%), gall bladder (1/5; 1.5%), ascending aorta (1/59; 1.5%), thyroid (1/59; 1.5%). The incidence of malignant incidental findings resulted to be higher in the group of patients with personal breast cancer (36%) than in the other one (8%). By comparing MRI findings with the additional definitive imaging tools, breast MRI allowed a correct diagnosis in 58/59 cases with a diagnostic accuracy value of 98%.

CONCLUSION

Incidental extramammary findings on breast MRI are common. Benign lesions represent the most frequent findings, however malignant ones need to be searched especially in patients with personal history of breast cancer because they could influence the clinical patient management. Breast MRI can characterize incidental findings with high accuracy value.

Acoustic radiation force impulse elastography for focal hepatic tumors: usefulness for differentiating hemangiomas from malignant tumors

Objective

The purpose of this study is to investigate whether acoustic radiation force impulse (ARFI) elastography with ARFI quantification and ARFI 2-dimensional (2D) imaging is useful for differentiating hepatic hemangiomas from malignant hepatic tumors.

Materials and Methods

One-hundred-and-one tumors in 74 patients were included in this study: 28 hemangiomas, 26 hepatocellular carcinomas (HCCs), three cholangiocarcinomas (CCCs), 20 colon cancer metastases and 24 other metastases. B-mode ultrasound, ARFI 2D imaging, and ARFI quantification were performed in all tumors. Shear wave velocities (SWVs) of the tumors and the adjacent liver and their SWV differences were compared among the tumor groups. The ARFI 2D images were compared with B-mode images regarding the stiffness, conspicuity and size of the tumors.

Results

The mean SWV of the hemangiomas was significantly lower than the malignant hepatic tumor groups: hemangiomas, 1.80 ± 0.57 m/sec; HCCs, 2.66 ± 0.94 m/sec; CCCs, 3.27 ± 0.64 m/sec; colon cancer metastases, 3.70 ± 0.61 m/sec; and other metastases, 2.82 ± 0.96 m/sec (p < 0.05). The area under the receiver operating characteristics curve of SWV for differentiating hemangiomas from malignant tumors was 0.86, with a sensitivity of 96.4% and a specificity of 65.8% at a cut-off value of 2.73 m/sec (p < 0.05). In the ARFI 2D images, the malignant tumors except HCCs were stiffer and more conspicuous as compared with the hemangiomas (p < 0.05).

Conclusion

ARFI elastography with ARFI quantification and ARFI 2D imaging may be useful for differentiating hepatic hemangiomas from malignant hepatic tumors.

Surgical management of disappearing colorectal liver metastases

BACKGROUND

Owing to expanded surgical indications for colorectal liver metastasis (CRLM) and improved systemic therapy, hepatic surgeons are increasingly faced with the problem of disappearing (no longer visible on imaging) liver metastasis (DLM).

METHODS

A review of relevant studies was performed. Studies that reported on DLM associated with preoperative chemotherapy for CRLM were identified, and data were synthesized and tabulated. The PubMed database was searched for relevant articles published between January 2000 and December 2012.

RESULTS

A complete response on imaging does not necessarily equate with a complete clinical or pathological response. Rather, residual macroscopic disease is found in about 25-45 per cent of patients at the time of operation. Even among patients with a complete pathological response, long-term remission occurs in only 20-50 per cent of those treated with systemic therapy. A durable response of DLM is more common following the use of hepatic artery infusion therapy.

CONCLUSION

Liver resection should include all original sites of disease if possible.

Timing of the hepatic arterial phase at Gd-EOB-DTPA-enhanced hepatic dynamic MRI: comparison of the test-injection and the fixed-time delay method

PURPOSE

To compare the fixed-time- and the test-injection method with respect to the image quality of hypervascular hepatocellular carcinoma (HCC) and the adequacy of timing of the hepatic arterial phase (HAP) in Gd-EOB-DTPA (EOB) enhanced MRI.

MATERIALS AND METHODS

We studied 63 patients with computed tomography (CT) -proven hypervascular HCC: 30 (group 1) were scanned HAP using the fixed-time delay method (protocol 1); in the other 33 (group 2), we applied the test-injection method (protocol 2). We compared the protocols with respect with tumor-to-liver contrast (TLC), contrast-to-noise-ratio (CNR), and relative enhancement of the liver and tumor (REL , RET ) during HAP. Two radiologists compared the adequacy of HAP, image contrast, image noise, and overall image quality.

RESULTS

Under protocol 2, TLC, CNR, and REL and RET of hypervascular HCC were significantly higher (P < 0.01). The proportion of optimal HAP was significantly higher for protocol 2 than protocol 1 (P < 0.01). The visual score of the image contrast and the overall image quality were significantly higher in group 2 than group 1 (P = 0.02 and P = 0.01, respectively).

CONCLUSION

At EOB-enhanced hepatic dynamic MRI, the test-injection method yielded better image quality of hypervascular HCC and improved adequacy of timing of HAP.

[Radiological diagnosis of primary hepatic malignancy]

Modern radiology offers countless opportunities both in the detection but also in the characterization of primary liver malignancies. Ultrasound remains usually the first exploratory overview study whereat using ultrasound contrast agent for a further characterization of liver lesions improves this technique considerably. Advanced cross-sectional imaging methods can, in most cases, already provide an exact diagnosis. Thus, the CT is already considered a standard technique for liver imaging and magnetic resonance imaging has gained in recent years due to liver-specific contrast agents and faster sequences a central role in liver imaging. The following article provides an overview of these various radiological procedures and describes the different primary liver malignancies and their imaging characteristics.

Extra-mammary findings in breast MRI

OBJECTIVES

Incidental extra-mammary findings in breast Magnetic Resonance Imaging (MRI) may be benign in nature, but may also represent a metastasis or another important lesion. We aimed to analyse the prevalence and clinical relevance of these unexpected findings.

METHODS

A retrospective review of 1535 breast MRIs was conducted. Only axial sequences were reassessed. Confirmation examinations were obtained in all cases.

RESULTS

285 patients had a confirmed incidental finding, which were located in the liver (51.9%), lung (11.2%), bone (7%), mediastinal lymph nodes (4.2%) or consisted of pleural/pericardial effusion (15.4%). 20.4% of incidental findings were confirmed to be malignant. Positive predictive value for MRI to detect a metastatic lesion was high if located within the bone (89%), lymph nodes (83%) and lung (59%), while it was low if located within the liver (9%) or if it consisted of pleural/pericardial effusion (6%). The axial enhanced sequence showed superior sensitivity to unenhanced images in detecting metastatic lesions, especially if only smaller (≤10 mm.) lesions were considered.

CONCLUSIONS

The prevalence of metastatic incidental extra-mammary findings is not negligible. Particular attention should be to incidental findings located within the lung, bone and mediastinal lymph nodes.

The role of hepatocyte-specific staining in liver pathology

The advantages of MRI in the investigation of liver disease are well documented. Recent developments, including fast scanning technique and new MRI contrast agents, enable improved detection and characterization of focal liver lesions. Therefore, a definitive diagnosis can be made avoiding invasive procedures, such as liver biopsy. In this article, a special emphasis is placed on the clinical use of combined perfusional and hepatocyte-selective MRI contrast agents, which allow us to obtain morphologic and vascular information, owing to the dynamic study, as well as functional information, owing to the hepatocyte-selective phase of enhancement. Different clinical scenarios are considered in order to highlight the proper use of the hepatocyte phase to noninvasively characterize and detect different focal liver lesions.

MR-arterioportography: A new technical approach for detection of liver lesions

AIM: To evaluate the benefit and effectiveness of MR-arterioportography (MR-AP) to achieve the highest sensitivity for detection and evaluation of hepatocellular carcinoma (HCC).

METHODS: Twenty liver cirrhosis patients with suspected HCC were included before transarterial chemoembolization. In all patients double-enhanced Magnetic resonance imaging (MRI) was performed. A bolus of 10 mL Magnevist^® was injected through a selectively placed catheter in the superior mesenteric artery and MRI of the liver was performed in arterioportographic phase. Two independent readers evaluated number, size and localization of detected lesions. Diagnostic quality was determined using a 4-point scale. Differences were analyzed for significance using a t-test. Interobserver variability was calculated.

RESULTS: In all 20 patients (100%), MR-AP was feasible. Diagnostic quality was, in all cases, between 1 and 2 for both modalities and readers. MR-AP detected significantly more lesions than double-enhanced MRI (102.5 vs 61, respectively, P < 0.0024). The inter-observer variability was 0.881 for MRI and 0.903 for MR-AP.

CONCLUSION: Our study confirmed that the MR-AP as an additional modality for detection of HCC is beneficial, as significantly more lesions were detected compared to MRI with liver-specific contrast.

Characterisation of small hypoattenuating hepatic lesions in multi-detector CT (MDCT) in patients with underlying extrahepatic malignancy: added value of contrast-enhanced MR images

OBJECTIVE

To retrospectively assess the value of adding gadolinium-enhanced dynamic imaging to standard ununenhanced magnetic resonance imaging (MRI) for characterising hypoattenuating hepatic lesions that are too small to characterise with multi-detector computed tomography (MDCT).

METHODS

Informed consent was waved, and institutional review board approval was obtained. Three hundred and forty-six small (≤ 2 cm) lesions (63 metastatic, 283 benign) in 183 patients with underlying carcinoma who underwent hepatic MRI after CT were retrospectively analysed. Two radiologists independently reviewed images and diagnoses were graded on an ordinal scale from 1 (definitely benign) to 5 (definitely malignant). Receiver operating characteristic analysis was used. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy were also determined.

RESULTS

The areas under the curve of the ununenhanced images alone and with dynamic images were 0.837 and 0.850 for reader 1 (p = 0.616) and 0.771 and 0.783 for reader 2 (p = 0.700). Descriptive statistical values demonstrated sensitivities of 76% and 80%, specificities of 93% and 95%, PPVs of 69% and 79%, NPVs of 95% and 95% and accuracies of 90% and 92%, respectively.

CONCLUSION

The value of adding three-phase contrast-enhanced MRI to unenhanced imaging did not reach statistical significance for characterising small hypoattenuating hepatic lesions on MDCT.

MR imaging correlates of intratumoral tissue types within colorectal liver metastases: a high-spatial-resolution fresh ex vivo radiologic-pathologic correlation study

PURPOSE

To analyze the direct relationship between complex internal magnetic resonance (MR) signal intensity (SI) patterns observed in colorectal liver metastases and their microscopic tissue characteristics.

MATERIALS AND METHODS

The institutional ethics board approved this study. In seven consecutive patients undergoing hepatic resection for liver metastases (primary colorectal in six, breast mistaken for colorectal in one), the resected fresh ex vivo liver specimen was examined with T1-weighted (repetition time msec/echo time msec, 9/4.4-4.8) and T2-weighted (2500/90) MR imaging by using a voxel size of 0.47 x 0.7 x 2 mm. The liver was sectioned in a concordant plane, and individual histologic slides were scanned and reconstructed to form a whole-mount pathologic image of the metastases. A pathologist identified the regions of interest for intraacinar necrosis (IAN), loose or dense fibrosis, and moderately and poorly differentiated cells within the metastases, and these regions were matched to the corresponding MR image. The morphologic and SI patterns were noted. The normalized ratio between the SI of these regions and that of the background liver was determined on T1- and T2-weighted images. Pairwise differences between tissue types were calculated by using linear mixed model, with the P values adjusted for multiple comparisons by using the method of Sidak.

RESULTS

A total of 98 zones were defined after pathologic analysis. On T2-weighted images, IAN was significantly lower in SI (P < .05) than the other tissues types. On T1-weighted images, IAN was significantly higher in SI than the other tissues types (P < .001). The type of necrosis encountered in these specimens was exclusively IAN. Qualitatively IAN had a specific pattern of SI (hypointense on T2-weighted and hyperintense on T1-weighted images). Other tissues types, including fibrosis, showed a pattern of hyperintensity on T2-weighted and hypointensity on T1-weighted images.

CONCLUSION

IAN seen in colorectal metastases exhibits high T1-weighted SI and mixed T2-weighted SI. This SI pattern is unusual for common benign liver lesions and may be helpful in the MR imaging diagnosis of colorectal liver metastases. (c) RSNA, 2010.

Computer-aided diagnosis of focal liver lesions by use of physicians' subjective classification of echogenic patterns in baseline and contrast-enhanced ultrasonography

RATIONAL AND OBJECTIVES

To develop a computer-aided diagnostic (CAD) scheme for classifying focal liver lesions (FLLs) by use of physicians' subjective classification of echogenic patterns of FLLs on baseline and contrast-enhanced ultrasonography (US).

MATERIALS AND METHODS

A total of 137 hepatic lesions in 137 patients were evaluated with B-mode and NC100100 (Sonazoid)-enhanced pulse-inversion US; lesions included 74 hepatocellular carcinomas (HCCs) (23: well-differentiated, 36: moderately differentiated, 15: poorly differentiated HCCs), 33 liver metastases, and 30 liver hemangiomas. Three physicians evaluated single images at B-mode and arterial phases with a cine mode. Physicians were asked to classify each lesion into one of eight B-mode and one of eight enhancement patterns, but did not make a diagnosis. To classify five types of FLLs, we employed a decision tree model with four decision nodes and four artificial neural networks (ANNs). The results of the physicians' pattern classifications were used successively for four different ANNs in making decisions at each of the decision nodes in the decision tree model.

RESULTS

The classification accuracies for the 137 FLLs were 84.8% for metastasis, 93.3% for hemangioma, and 98.6% for all HCCs. In addition, the classification accuracies for histological differentiation types of HCCs were 65.2% for well-differentiated HCC, 41.7% for moderately differentiated HCC, and 80.0% for poorly differentiated HCC.

CONCLUSIONS

This CAD scheme has the potential to improve the diagnostic accuracy of liver lesions. However, the accuracy in the histologic differential diagnosis of HCC based on baseline and contrast-enhanced US is still limited.

Receiver operating characteristic analysis of diffusion-weighted magnetic resonance imaging in differentiating hepatic hemangioma from other hypervascular liver lesions

PURPOSE

To evaluate the role of diffusion-weighted imaging in differentiating between hepatic hemangiomas, both typical and atypical, and other hypervascular liver lesions.

METHODS

Retrospective review of 182 hypervascular liver lesions in 117 patients was performed. Diffusion and contrast-enhanced magnetic resonance imaging were performed using a 1.5-T unit. Imaging protocol consisted of T2-weighted fast spin-echo images, breath-hold diffusion-weighted echo-planar images, and breath-hold unenhanced and contrast-enhanced T1-weighted 3-dimensional fat-suppressed spoiled gradient-echo images in the arterial phase (20 seconds) and portal venous phase (60 seconds). Signal intensity changes and apparent diffusion coefficient (ADC) values were evaluated for all lesions. Unpaired t test was used to compare the mean ADC values for different lesions, and statistical significance was set at P < 0.01. Receiver operating characteristic analysis was used to determine the accuracy of diffusion-weighted imaging in differentiating hemangiomas from other hypervascular liver lesions.

RESULTS

Lesions included typical and atypical hemangioma (n = 38), hepatocellular carcinoma (HCC; n = 58), focal nodular hyperplasia (FNH; n = 22), and neuroendocrine tumor metastasis (NET; n = 64) with a mean tumor size of 5.3 cm. Mean ADC value for hemangioma, HCC, FNH, and NET was 2.29 x 10(-3), 1.55 x 10(-3), 1.65 x 10(-3), and 1.43 x 10(-3) mm2/s, respectively. There was a statistically significant difference in the ADC value of hemangioma compared with that of FNH (P < 0.001), HCC (P < 0.001), and NET (P < 0.001), respectively. The area under the receiver operating characteristic curve was 0.91.

CONCLUSIONS

Diffusion-weighted magnetic resonance imaging and ADC maps can provide rapid quantifiable information to differentiate typical and atypical hemangiomas from other hypervascular liver lesions.

Computer-aided diagnosis for the classification of focal liver lesions by use of contrast-enhanced ultrasonography

The authors developed a computer-aided diagnostic (CAD) scheme for classifying focal liver lesions (FLLs) as liver metastasis, hemangioma, and three histologic differentiation types of hepatocellular carcinoma (HCC), by use of microflow imaging (MFI) of contrast-enhanced ultrasonography. One hundred and three FLLs obtained from 97 cases used in this study consisted of 26 metastases (15 hyper- and 11 hypovascularity types), 16 hemangiomas (five hyper- and 11 hypovascularity types) and 61 HCCs: 24 well differentiated (w-HCC), 28 moderately differentiated (m-HCC), and nine poorly differentiated (p-HCC). Pathologies of all cases were determined based on biopsy or surgical specimens. Locations and contours of FLLs on contrast-enhanced images were determined manually by an experienced physician. MFI was obtained with contrast-enhanced low-mechanical-index (MI) pulse subtraction imaging at a fixed plane which included a distinctive cross section of the FLL. In MFI, the inflow high signals in the plane, which were due to the vascular patterns and the contrast agent, were accumulated following flash scanning with a high-MI ultrasound exposure. In the initial step of our computerized scheme, a series of the MFI images was extracted from the original cine clip (AVI format). We applied a smoothing filter and time-sequential running average techniques in order to reduce signal noise on the single MFI image and cyclic noise on the sequential MFI images, respectively. A kidney, vessels, and a liver parenchyma region were segmented automatically by use of the last image of a series of MFI images. The authors estimated time-intensity curves for an FLL by use of a series of the temporally averaged MFI images in order to determine temporal features such as estimated replenishment times at early and delayed phases, flow rates, and peak times. In addition, they extracted morphologic and gray-level image features which were determined based on the physicians' knowledge of the diagnosis of the FLL, such as the size of lesion, vascular patterns, and the presence of hypoechoic regions. They employed a cascade of six independent artificial neural networks (ANNs) by use of extracted temporal and image features for classifying five types of liver diseases. A total of 16 temporal and image features, which were selected from 43 initially extracted features, were used for six different ANNs for making decisions at each decision in the cascade. The ANNs were trained and tested with a leave-one-lesion-out test method. The classification accuracies for the 103 FLLs were 88.5% for metastasis, 93.8% for hemangioma, and 86.9% for all HCCs. In addition, the classification accuracies for histologic differentiation types of HCCs were 79.2% for w-HCC, 50.0% for m-HCC, and 77.8% for p-HCC. The CAD scheme for classifying FLLs by use of the MFI on contrast-enhanced ultrasonography has the potential to improve the diagnostic accuracy in the histologic diagnosis of HCCs and the other liver diseases.

Double-contrast MRI for accurate staging of hepatocellular carcinoma in patients with cirrhosis

OBJECTIVE

The aim of this study was to evaluate the accuracy of a double-contrast MRI protocol in staging of hepatocellular carcinoma (HCC) in patients with cirrhosis.

MATERIALS AND METHODS

This cross-sectional study was performed at a tertiary liver care center. Forty-eight patients with cirrhosis underwent double-contrast MRI for clinical care and liver transplantation. For each MRI examination, superparamagnetic iron oxide was infused, and 2D T2*-weighted spoiled gradient-recalled echo and T2-weighted echo-train spin-echo MR images were obtained for assessment of phagocytic function. Immediately afterward, a low-molecular-weight gadolinium compound was injected, and 3D T1-weighted spoiled gradient-recalled echo images were acquired dynamically for assessment of vascularity. Two blinded radiologists independently reviewed all MR images and assigned per-lesion and per-patient cancer confidence scores to determine the American Liver Tumor Study Group tumor stage. The imaging-based cancer scores and tumor stages were correlated with pathology reports. Performance parameters were computed for imaging-based measurements.

RESULTS

Of the 48 study subjects, 25 had HCC (three, T1; 18, T2; one, T3; one, T4a; two, T4b). In total, there were 37 HCC nodules. The accuracy of MRI in prediction of pathologic tumor stage was 81-85% depending on the radiologist. Per-patient and per-lesion sensitivity in the diagnosis of HCC were 96% and 81% for one radiologist and 96% and 89% for the other.

CONCLUSION

A double-contrast MRI protocol has high accuracy in staging of HCC in patients with cirrhosis.

Usefulness of Combining Sequentially Acquired Gadobenate Dimeglumine-Enhanced Magnetic Resonance Imaging and Resovist-Enhanced Magnetic Resonance Imaging for the Detection of Hepatocellular Carcinoma

OBJECTIVE

To investigate the diagnostic efficacy of sequentially acquired gadobenete dimeglumine-enhanced 3-dimensional dynamic magnetic resonance imaging (MRI) and Resovist-enhanced MRI for detecting hepatocellular carcinoma (HCC) by comparing with combined computed tomography (CT) hepatic arteriography (CTHA) and CT arterioportography (CTAP) using 16-slice multidetector CT.

MATERIALS

Twenty-nine patients with 50 HCCs underwent sequentially acquired double-contrast MRI--gadobenate dimeglumine-enhanced dynamic MRI and Resovist-enhanced MRI--and combined CTHA and CTAP using 16-slice multidetector CT. Dynamic MRI was obtained using volumetric interpolated technique and sensitivity encoding on a 1.5-T unit. Resovist-enhanced MRI was composed of T2-weighted turbo spin-echo and T2*-weighted gradient echo sequences. Sensitivity, positive predictive value, and diagnostic accuracy for double-contrast MRI, gadolinium-enhanced MRI, and combined CTHA and CTAP were calculated by 2 observers using an alternative-free response receiver operating characteristic analysis.

RESULTS

For all observers, the Az values of double-contrast MRI (mean, 0.96) and combined CTHA and CTAP (mean, 0.93) were similar, which tended to be better than that of gadolinium-enhanced MRI (mean, 0.91). The sensitivity of double-contrast MRI (mean, 93%) and combined CTHA and CTAP (mean, 92%) was equivalent for all observers, which was better than that of gadolinium-enhanced MRI (mean, 85%; P < 0.05). The positive predictive value of double-contrast MRI was better than that of combined CTHA and CTAP (P < 0.05).

CONCLUSION

The sequentially acquired double-contrast MRI and combined CTHA and CTAP showed a similar diagnostic accuracy and sensitivity for detecting HCC.

Surgical therapy for colorectal metastases to the liver

Colorectal cancer is the fourth most common type of cancer in the West and the second leading cause of cancer-related deaths in the United States. Approximately 35 to 55% of patients with colorectal cancer develop hepatic metastases during the course of their disease. Surgical resection of colorectal liver metastases represents the only chance at potential cure, and long-term survival can be achieved in 35 to 58% of patients after resection. The goal of hepatic resection should be to resect all metastases with negative histologic margins while preserving sufficient functional hepatic parenchyma. In patients with extensive metastatic disease who would otherwise be unresectable, ablative approaches can be used instead of or combined with hepatic resection. The use of portal vein embolization and preoperative chemotherapy may also expand the population of patients who are candidates for surgical treatment. Despite these advances, many patients still experience a recurrence after hepatic resection. More active systemic chemotherapy agents are now available and are being increasingly employed as adjuvant therapy either before or after surgery. Modern treatment of colorectal liver metastasis requires a multidisciplinary approach in an effort to increase the number of patients who may benefit from surgical treatment of colorectal cancer liver metastasis.

Apresentações incomuns do hemangioma hepático: ensaio iconográfico

O nosso objetivo foi descrever e ilustrar aspectos incomuns do hemangioma hepático na ultra-sonografia (US), tomografia computadorizada (TC) e ressonância magnética (RM). A partir da análise retrospectiva de 300 casos de pacientes com diagnósticos de hemangioma hepático, por meio da análise combinada de exames de imagem, biópsia ou acompanhamento clínico, selecionamos aqueles com apresentação atípica em um ou mais métodos de imagem ou aqueles com evolução não usual, ilustrando os seus principais aspectos de imagem. Entre os casos apresentados, escolhemos pacientes com hemangiomas: hipoecogênicos na US; hipovasculares ou avasculares na TC e RM; com calcificações grosseiras; gigantes e medindo mais de 20 cm de diâmetro; predominantemente exofíticos; hipointensos em T2; promovendo defeito de perfusão; com cicatriz central e simulando hiperplasia nodular focal; com crescimento evolutivo. O hemangioma hepático é o tumor mais comum do fígado e geralmente tem apresentação típica. Porém, os seus diversos aspectos não usuais precisam ser conhecidos para auxiliar na orientação diagnóstica e conduta.

Hepatic metastases: perilesional enhancement on dynamic MRI

OBJECTIVE

Our purpose was to determine whether the perilesional parenchymal enhancement of hepatic metastases could be correlated with tumoral enhancement on arterial phase images or tumor size on dynamic MRI.

MATERIALS AND METHODS

One hundred thirty-four lesions of hepatic metastases in 44 patients were subjected to a retrospective analysis of the dynamic MR images obtained with 3D spoiled gradient-echo sequences. The thickness of the enhancing rim on arterial phase images was regarded as a summation of the enhancing component of tumor periphery and perilesional enhancement, which were estimated by the tumor size on precontrast T1-weighted images. The presence of wedge-shaped perilesional enhancement was also correlated with the lesion size.

RESULTS

Except for 17 diffusely enhanced lesions, lesion size was comparable between the lesions with (n = 87; 26 +/- 19 [SD] mm) and without rim enhancement (n = 30; 27 +/- 23 mm) on the arterial phase dynamic MR images (p > 0.05). The degree of peripheral tumoral enhancement showed an inverse correlation (r = -0.389) with the thickness of the circumferential perilesional enhancement (p < 0.001). The mean size of the lesions with wedge-shaped perilesional enhancement (n = 44; 33 +/- 20 mm) was larger than that of the other lesions (n = 90; 25 +/- 19 mm) (p = 0.016).

CONCLUSION

The degree of circumferential perilesional enhancement of hepatic metastases on arterial phase dynamic MR images would be independent of the lesion size but inversely correlated with the degree of peripheral tumoral vascularity. An understanding of these features may help tumor characterization and should prompt hypotheses and studies of microvascular phenomena in tumoral and epitumoral environments.

Dysplastic nodules frequently develop into hepatocellular carcinoma in patients with chronic viral hepatitis and cirrhosis

BACKGROUND

Advances in imaging technology have enhanced the detection of small nodular lesions during the course of chronic liver disease.

METHODS

Between 1995 and 2002, the authors examined 154 consecutive patients with small hepatic nodules without hepatocellular carcinoma (HCC) over a median duration of 2.8 years. The median size of these nodules was 14 mm (range, 7-40 mm). The initial histopathologic diagnosis included high-grade dysplastic nodule (HGDN) (n=13), low-grade dysplastic nodule (LGDN) (n=42), and regenerative nodule (RN) (n=99).

RESULTS

A total of 29 (18.8%) nodules developed into HCC during the observation period. Cumulative HCC development rates at the first, third, and fifth year were 46.2%, 61.5%, and 80.8% for HGDN; 2.6%, 30.2%, and 36.6% for LGDN; and 3.3%, 9.7%, and 12.4% for RN, respectively. The rate of HCC development was significantly higher in the HGDN group than for other types (P<0.001). Multivariate analysis disclosed that histopathologic diagnosis (P<0.001) and findings on computed tomographic arterial portography (CT-AP) (P=0.004) were significantly associated with future HCC development. The hazard ratios of HGDN and LGDN were 16.8 (95% confidence interval [CI], 6.19-45.6) and 2.96 (95% CI, 1.20-7.31), respectively. A decrease in portal blood flow also showed a significantly high hazard ratio of 3.04 (95% CI, 1.42-6.50). Approximate annual development rate to HCC was 20% in patients with HGDN and 10% in LGDN.

CONCLUSION

HGDN should be considered a precancerous lesion when it appears during follow-up of chronic viral hepatitis or cirrhosis. Reduced portal blood flow in the nodule on computed tomography-AP is also an important predictor for development of hepatocellular carcinoma.

Contrast-enhanced dynamic magnetic resonance imaging findings of hepatocellular carcinoma and their correlation with histopathologic findings

PURPOSE

To investigate the correlations of contrast-enhanced magnetic resonance (MR) imaging findings of large (> 5 cm) hepatocellular carcinomas with tumor size and histopathologic findings.

MATERIALS AND METHODS

MR imaging was performed in 30 patients with a histopathologic diagnosis of hepatocellular carcinoma. The imaging protocol included non-contrast, hepatic arterial, portal venous and late phases. The signal intensities relative to the liver, enhancement patterns and the morphologic features of the lesions were evaluated in relation to size and degree of differentiation.

RESULTS

On histopathologic examination, 12 of 30 (40%) tumors were well-differentiated (grade 1), 6 of 30 (20%) were moderately differentiated (grades 2 and 3) and 12 of 30 (40%) were poorly differentiated (grade 4). Tumor size, tumor boundry, serum alpha-fetoprotein level and portal vein invasion were found to have statistically significant correlations with the degree of differentiation (p < 0.05). Portal vein invasion, capsule formation and tumor surface characteristics showed statistically significant correlations with tumor size (p < 0.05).

CONCLUSION

MR imaging findings of hepatocellular carcinomas larger than 5 cm are partially dependent on tumor size and degree of differentiation.

Eosinophilic Hepatic Necrosis

OBJECTIVE

To compare the findings of magnetic resonance (MR) imaging with those of computed tomography (CT) of focal liver lesions related to peripheral eosinophilia.

METHODS

For 12 patients with peripheral eosinophilia (>7%) examined with hepatic MR imaging and CT, 52 focal hepatic lesions larger than 0.5 cm, including 31 lesions simultaneously found on the 2 imaging modalities, were subjected to a comparative analysis of their imaging features.

RESULTS

The total number of lesions distinguished from background liver was 39 (75%) on MR imaging and 44 (85%) on CT scans. On arterial phase images of 10 patients with comparable data, homogeneously hyperintense lesions were demonstrated more frequently (P = 0.006) on MR imaging (16 [50%] of 32 lesions) than on CT scans (4 [13%] of 32 lesions). Only 7 (22%) of the 32 hypoattenuating lesions on portal phase CT were depicted as hypointense lesions on portal phase MR images in 12 patients. On delayed phase images in 8 patients, the number of hyperintense lesions on MR images (9 [56%] of 16) was greater (P = 0.077) than that seen on the CT scans (4 [25%] of 16).

CONCLUSIONS

For many focal hepatic lesions related to peripheral eosinophilia, dynamic MR imaging more easily demonstrates lesional enhancement on arterial and delayed phases than CT scans. Because of the higher degree of lesional enhancement of MR imaging compared with CT, the lesion-to-liver contrast may not be sufficient to distinguish the lesion from the background liver, resulting in decreased sensitivity of portal phase dynamic MR imaging.

Distinguishing Hepatic Metastases From Hemangiomas

OBJECTIVE

To determine the relative value of qualitative (reader opinion) and quantitative (values derived from dual echo T2 fast spin echo [FSE]) measures in distinguishing hepatic metastases from hemangiomas.

METHODS

Forty-nine patients with hemangiomas and 23 with metastases were studied with dual echo respiratory-triggered FSE and dynamic 2-dimensional spoiled gradient echo (GRE) imaging. Lesion T2 was estimated from signal intensity ratios on the first and second echoes. Two experienced radiologists independently evaluated groups of images based on 5 separate qualitative measures: first echo FSE, second echo FSE, first and second echo FSE, dynamic GRE, and all images together.

RESULTS

The mean calculated T2s were 226 +/- 74 milliseconds for hemangiomas and 105 +/- 22 milliseconds for metastases (P < 0.001). A T2 cutoff of 130 milliseconds distinguished metastases from hemangiomas with a sensitivity of 94%, specificity of 91%, and accuracy of nearly 94%. There was no significant difference between the best quantitative measure and the best qualitative measure for either reader.

CONCLUSION

Liver lesion T2 relaxation times calculated from dual echo FSE images provide information useful in discriminating metastases from hemangiomas, as does reader opinion.

Characterization of Hepatocellular Tumors

PURPOSE

To assess the value of mangafodipir trisodium-enhanced MR imaging for characterization of hepatocellular lesions.

MATERIALS AND METHODS

Magnetic resonance images of 41 patients with 48 histopathologically proven hepatocellular lesions (20 cases of focal nodular hyperplasia [FNH], 4 adenomas, 15 hepatocellular carcinomas [HCCs], 7 regenerative nodules, and 2 others) were retrospectively studied. Magnetic resonance imaging was performed on a 1.5-T unit (Vision, Siemens, Erlangen, Germany; ACS-NT, Philips, Best, The Netherlands) using T2-weighted, fat-saturation, turbo spin echo imaging and T1-weighted gradient echo imaging before and 20 minutes after infusion of 5 micromol/kg mangafodipir (Amersham Health, Oslo, Norway). Qualitative analysis by 4 blinded independent readers included assessment of unenhanced images and, in a second step, assessment of unenhanced and contrast-enhanced images together. Lesions were classified as benign or malignant using a 5-point scale, and readers made a specific diagnosis.

RESULTS

For characterization of hepatocellular lesions, mangafodipir-enhanced imaging was significantly superior to unenhanced imaging (P < 0.05). On receiver operating characteristic analysis, the area under the curve was 0.768 (95% confidence interval: 0.633-0.903) for unenhanced images and 0.866 (95% confidence interval: 0.767-0.966) for evaluation of unenhanced and contrast-enhanced images together (P < 0.05). Analysis of enhancement patterns aided in characterization and classification of tumors.

CONCLUSION

Administration of mangafodipir improves the differentiation between adenoma or HCC and "nonsurgical" lesions (FNH or regenerative nodules). The accuracy for arriving at a specific diagnosis is higher when unenhanced and mangafodipir-enhanced images are considered together than for unenhanced MR images alone.

MRI for Detection of Hepatocellular Carcinoma: Comparison of Mangafodipir Trisodium and Gadopentetate Dimeglumine Contrast Agents

OBJECTIVE

The purpose of our study was to compare the performance of mangafodipir trisodium (Mn-DPDP)-enhanced and dynamic gadopentetate dimeglumine-enhanced MRI for the detection of hepatocellular carcinoma.

MATERIALS AND METHODS

Forty-six patients with 96 hepatocellular carcinomas underwent Mn-DPDP- and gadopentetate dimeglumine-enhanced MRI. The MRI examination included unenhanced T2-weighted turbo spin-echo and T1-weighted 2D fast low-angle shot (FLASH) sequences and a 3D FLASH sequence after the administration of gadopentetate dimeglumine and Mn-DPDP. Two observers reviewed three sets of images: a set of gadopentetate dimeglumine-enhanced MR images, a set of Mn-DPDP-enhanced MR images, and a combination of the gadopentetate dimeglumine and Mn-DPDP sets. Using receiver operating characteristic (ROC) analysis, imaging sets were compared for diagnostic accuracy and sensitivity.

RESULTS

The area under the ROC curve (A(z)) was 0.942 for the gadopentetate dimeglumine-Mn-DPDP set, 0.932 for the gadopentetate dimeglumine set, and 0.877 for the Mn-DPDP set (p < 0.05). The mean sensitivity was greater for the gadopentetate dimeglumine set than for the Mn-DPDP set (87.5% vs 72.4%; p < 0.05). The false-negative rate of the Mn-DPDP set was statistically greater than that of the gadopentetate dimeglumine set (27.6% vs 12.5%). Most false-negative cases in the Mn-DPDP set were due to small (diameter < 2 cm), isoenhanced lesions.

CONCLUSION

Gadopentetate dimeglumine-enhanced MRI was superior to Mn-DPDP-enhanced MRI for the detection of hepatocellular carcinomas.

Detection of hepatocellular carcinoma using double-echo FLASH sequence during the hepatic arterial phase

PURPOSE

The purpose of this study was to compare the performance of in-phase and opposed-phase gradient-recalled echo (GRE) pulse sequences in paramagnetic contrast-enhanced magnetic resonance (MR) imaging of hepatocellular carcinomas (HCCs) during the hepatic arterial phase.

MATERIAL AND METHODS

Thirty-four patients with 84 lesions with known or suspected HCCs, nine of whom had a fatty liver, were examined with double-echo GRE techniques under 1.5T before and 30 s after injection of gadopentenate dimeglumine at a dose of 0.1 mmol/kg. Echo times were 2.4 ms (opposed phase) and 5.0 ms (in phase). Contrast enhancement of the HCC detected in both in-phase and opposed-phase images was evaluated. The liver signal-to-noise ratio (SNR), lesion-liver contrast-to-noise ratio (CNR), and enhancement ratio (ER) were calculated for the largest lesion of each patient.

RESULTS

In dynamic gadolinium-enhanced images of the 84 HCCs, 81 (96.4%) were detected in both in-phase and opposed-phase images, two (2.4%) were detected in only in-phase images, and one (1.2%) was detected only in opposed-phase images. The liver SNR, CNR, and ER were 46.7+/-16.1, 15.2+/-10.3, and 0.637+/-0.268 for in-phase images, and 48.9+/-16.9, 16.3+/-11.8, and 0.647+/-0.309 for opposed-phase images, respectively. In patients with a fatty liver, the SNR, CNR, and ER were 46.0+/-18.1, 21.7+/-17.9, and 0.525+/-0.231 for in-phase images, and 44.3+/-18.7, 26.0+/-21.3, and 0.793+/-0.124 for opposed-phase images, respectively. No significant statistical differences were found between the in-phase and opposed-phase images.

CONCLUSION

Opposed-phase GRE imaging is equivalent to in-phase GRE sequences in patients with or without fatty liver for detection of HCC in dynamic gadolinium-enhanced images.

Comparison of Superparamagnetic Iron Oxide–Enhanced and Gadobenate Dimeglumine–Enhanced Dynamic MRI for Detection of Small Hepatocellular Carcinomas

OBJECTIVE

The purpose of this study was to compare superparamagnetic iron oxide (SPIO)-enhanced MRI with gadobenate dimeglumine-enhanced MRI for the detection of hepatocellular carcinoma using receiver operating characteristic (ROC) analysis.

MATERIALS AND METHODS

Twenty-nine consecutive patients with 35 hepatocellular carcinomas underwent gadobenate dimeglumine-enhanced MRI (unenhanced, arterial, portal, and equilibrium phases) using 3D fat-saturated volumetric interpolated imaging and SPIO-enhanced MRI on a 1.5-T unit. SPIO-enhanced T2-weighted turbo spin-echo and T2*-weighted gradient-echo sequences were performed 48 hr after completion of the dynamic study. Three observers independently interpreted the images in random order, separately, and without patient identifiers. Diagnostic accuracy was evaluated using the alternative free response receiver operating characteristic method. Sensitivity and positive predictive value were also evaluated.

RESULTS

The mean sensitivity and positive predictive value of SPIO-enhanced imaging were 81.0% and 85.0%, respectively, and those of gadobenate dimeglumine-enhanced MRI were 91.4% and 88.1%, respectively. A significant difference was seen in the sensitivity of the two MRI examinations (p < 0.05). The mean value of the area under the ROC curve (A(z)) for gadobenate dimeglumine-enhanced imaging (A(z) = 0.97 +/- 0.01) was significantly higher than that for SPIO-enhanced imaging (A(z) = 0.90 +/- 0.02) (p = 0.004).

CONCLUSION

Gadobenate dimeglumine-enhanced 3D dynamic imaging showed better diagnostic performance than SPIO-enhanced imaging for the detection of hepatocellular carcinomas.

Detection of malignant hepatic tumors with ferumoxide-enhanced MR imaging: usefulness of multishot and single-shot fast spin echo sequences

The purpose of our study was to assess whether respiratory-triggered multishot fast spin echo (MS-FSE) and breath-hold half-Fourier single-shot fast spin echo (SS-FSE) images, in addition to breath-hold T(2)*-weighted gradient recalled echo (GRE) images, increase observer performance in the detection of malignant hepatic tumors with ferumoxide-enhanced magnetic resonance (MR) imaging. Ferumoxide-enhanced MR images obtained from 48 patients with 83 malignant hepatic tumors were retrospectively reviewed by three independent off-site readers. In the first image review, GRE images alone were reviewed. Then, MS-FSE images were added for the first combination review. Finally, SS-FSE images were added for the second combination review. Observer performances were tested by McNemar's test and receiver-operating-characteristic analysis for the clustered data. Sensitivity for hepatocellular carcinomas, metastases, and malignant hepatic tumors overall was significantly (p < 0.05) higher with GRE and MS-FSE combined and GRE, MS-FSE and SS-FSE combined than with GRE alone. For metastases, the Az value was significantly (p < 0.05) higher with GRE and MS-FSE combined, and GRE, MS-FSE and SS-FSE combined than with GRE alone. We confirmed the incremental value of ferumoxide-enhanced MR imaging by obtaining MS-FSE and SS-FSE images in addition to GRE images in the detection of malignant hepatic tumors.

Detection of malignant hepatic tumors with ferumoxides-enhanced MRI: comparison of five gradient-recalled echo sequences with different TEs

OBJECTIVE

The purpose of our study was to compare the detectability of malignant hepatic tumors on ferumoxides-enhanced MRI using five gradient-recalled echo sequences at different TEs.

MATERIALS AND METHODS

Ferumoxides-enhanced MRIs obtained in 31 patients with 50 malignant hepatic tumors (33 hepatocellular carcinomas, 17 metastases) were reviewed retrospectively by three independent offsite radiologists. T1-weighted gradient-recalled echo images with TEs of 1.4 and 4.2 msec; T2*-weighted gradient-recalled echo images with TEs of 6, 8, and 10 msec; and T2-weighted fast spin-echo images of livers were randomly reviewed on a segment-by-segment basis. Observer performance was tested using the McNemar test and receiver operating characteristic analysis for the clustered data. Lesion-to-liver contrast-to-noise ratio was also assessed.

RESULTS

Mean lesion-to-liver contrast-to-noise ratios were negative and lower with gradient-recalled echo at 1.4 msec than with the other sequences. Sensitivity was higher (p < 0.05) with gradient-recalled echo at 6, 8, and 10 msec and fast spin-echo sequences (75-83%) than with gradient-recalled echo sequences at 1.4 and 4.2 msec (46-48%), and was higher (p < 0.05) with gradient-recalled echo sequence at 8 msec (83%) than with gradient-recalled echo at 6 msec and fast spin-echo sequences (75-78%). Specificity was comparably high with all sequences (95-98%). The area under the receiver operating characteristic curve (A(z)) was greater (p < 0.05) with gradient-recalled echo at 6, 8, and 10 msec and fast spin-echo sequences (A(z) = 0.91-0.93) than with gradient-recalled echo sequences at 1.4 and 4.2 msec (A(z) = 0.82-0.85).

CONCLUSION

In the detection of malignant hepatic tumors, gradient-recalled echo sequences at 8 msec showed the highest sensitivity and had an A(z) value and lesion-to-liver contrast-to-noise ratio comparable with values from gradient-recalled echo sequences at 6 and 10 msec and fast spin-echo sequences.

Malignant hepatic tumor detection with ferumoxide-enhanced magnetic resonance imaging: Is chemical-shift-selective fat suppression necessary for fast spin-echo sequence?

PURPOSE

To determine whether chemical-shift-selective (CSS) fat suppression is necessary for ferumoxide-enhanced T2-weighted fast spin-echo (FSE) imaging in the detection of malignant hepatic tumors.

MATERIALS AND METHODS

Ferumoxide-enhanced magnetic resonance (MR) images obtained in 38 patients with surgically confirmed 61 malignant hepatic tumors (36 hepatocellular carcinomas (HCCs), 25 metastases) were retrospectively reviewed by three independent readers. Three sequences of MR images with CSS fat-suppressed T2-weighted FSE, non-fat-suppressed T2-weighted FSE, and T2*-weighted gradient-recalled-echo (GRE) sequences were randomly reviewed on a segment-by-segment basis in a blind fashion. Observer performance was tested using the McNemar's test and receiver-operating-characteristic (ROC) analysis for the clustered data. Lesion-to-liver contrast-to-noise ratio (C/N) was also assessed.

RESULTS

The mean C/N with the CSS fat-suppressed FSE sequence was highest in HCCs, metastases, and tumors overall. Sensitivity was highest with the CSS fat-suppressed FSE sequence in HCC, was highest with the non-fat-suppressed FSE sequence in metastases, and was comparable in tumors overall. Specificity was comparable between the sequences. The area under ROC curve (Az) value was greatest with the CSS fat-suppressed FSE sequence in HCCs, was greatest with the non-fat- suppressed FSE sequence in metastases, and was comparable in tumors overall. The sensitivities and Az values were lower with the GRE sequence than the FSE sequence.

CONCLUSION

The CSS fat-suppressed FSE sequence was superior to the GRE sequence in the detection of HCCs, but the non-fat-suppressed FSE sequence was comparable to the GRE sequence. The non-fat-suppressed FSE sequence was superior to the CSS fat-suppressed FSE and GRE sequences in the detection of metastases. Optimal FSE imaging with CSS fat suppression or without aiming for the detection of HCCs or metastases, respectively, outperforms GRE imaging in ferumoxide-enhanced MRI.

Liver tumour MRI: what do we need for lesion characterization?

BACKGROUND

Hepatic lesions constitute a daily challenge to radiology in clinical settings, and non-invasive methods are valuable in the characterization of these liver tumours. We undertook our investigation to assess the lesion characterization potential of MRI by evaluating several unenhanced MR sequences and the dynamic gadolinium (Gd)-enhanced technique.

METHODS

A total of 116 focal liver lesions in 116 patients were included in our retrospective study, and histological verification was available for 107 lesions. Nine haemangiomas had a follow-up of 2 years. The 1.5-T MR system was used. T1- and T2-weighted sequences and dynamic Gd-enhanced studies were evaluated by two individual readers as separate sequences and also collectively. Lesions were classified into benign or malignant, and a specific diagnosis was proposed. The McNemar test was used in statistical analysis, and interobserver variation was measured using kappa statistics.

RESULTS

Lesion classification into benign and malignant tumours (by evaluating all images in concert) was assessed in 83% and 89% of cases by readers 1 and 2, respectively. From single sequences, best lesion classification was achieved with Gd-enhanced T1 by both readers. The difference in classification was statistically significant when all sequences were evaluated in comparison with any single sequence alone (P = 0.02). Specific diagnosis was correctly determined using all sequences together in 60% and 71% of cases by readers 1 and 2, respectively. For individual sequences, correct diagnosis was most frequently proposed with a Gd-enhanced T1-weighted sequence by both readers (59% and 65% for readers 1 and 2, respectively).

CONCLUSION

Multisequential MRI using Gd-enhanced imaging performs extremely well in liver lesion classification, and with moderate ability to determine a specific diagnosis.

Characterization of focal liver lesions with superparamagnetic iron oxide-enhanced MR imaging: value of distributional phase T1-weighted imaging

OBJECTIVE

To determine the potential value of distributional-phase T1-weighted ferumoxides-enhanced magnetic resonance (MR) imaging for tissue characterization of focal liver lesions.

MATERIALS AND METHODS

Ferumoxides-enhanced MR imaging was performed using a 1.5-T system in 46 patients referred for evaluation of known or suspected hepatic malignancies. Seventy-three focal liver lesions (30 hepatocellular carcinomas (HCC), 12 metastases, 15 cysts, 13 hemangiomas, and three cholangiocarcinomas) were evaluated. MR imaging included T1-weighted double-echo gradient-echo (TR/TE: 150/4.2 and 2.1 msec), T2*-weighted gradient-echo (TR/TE: 180/12 msec), and T2-weighted turbo spin-echo MR imaging at 1.5 T before and after intravenous administration of ferumoxides (15 mmol/kg body weight). Postcontrast T1-weighted imaging was performed within eight minutes of infusion of the contrast medium (distributional phase). Both qualitative and quantitative analysis was performed.

RESULTS

During the distributional phase after infusion of ferumoxides, unique enhancement patterns of focal liver lesions were observed for hemangiomas, metastases, and hepatocellular carcinomas. On T1-weighted GRE images obtained during the distributional phase, hemangiomas showed a typical positive enhancement pattern of increased signal; metastases showed ring enhancement; and hepatocellar carcinomas showed slight enhancement. Quantitatively, the signal-to-noise ratio of hemangiomas was much higher than that of other tumors (p <.05) and was similar to that of intrahepatic vessels. This finding permitted more effective differentiation between hemangiomas and other malignant tumors.

CONCLUSION

T1-weighted double-echo FLASH images obtained soon after the infusion of ferumoxides, show characteristic enhancement patterns and improved the differentiation of focal liver lesions.

Computed tomography and magnetic resonance imaging of hepatic metastases

The detection and characterization of liver metastases is well performed with either computed tomography or magnetic resonance imaging. The administration of intravenous contrast is essential for almost all indications, with multiphasic imaging aiding in lesion characterization and detection. The use of multidetected CT (MDCT) provides the ability for optimized vascular and multiplanar imaging, but has also resulted in increased examination complexity. Tissue-specific MR contrast agents can yield the highest rate of lesion detection and thus may be useful in presurgical planning.

Hepatocellular carcinoma: detection with gadolinium- and ferumoxides-enhanced MR imaging of the liver

PURPOSE

To test the hypothesis that the accuracy of gadolinium- and ferumoxides-enhanced magnetic resonance (MR) imaging is different in small (< or =1.5-cm) and large (>1.5-cm) hepatocellular carcinomas (HCCs).

MATERIALS AND METHODS

Forty-three consecutive patients with chronic liver disease were enrolled in this study. The imaging protocol included unenhanced breath-hold T1-weighted fast field-echo sequences, unenhanced respiratory-triggered T2-weighted turbo spin-echo (SE) sequences, dynamic gadolinium-enhanced T1-weighted three-dimensional turbo field-echo sequences, and ferumoxides-enhanced T2-weighted turbo SE sequences. Images of each sequence and two sets of sequences (ferumoxides set and gadolinium set) were reviewed by four observers. The ferumoxides set included unenhanced T1- and T2-weighted images and ferumoxides-enhanced T2-weighted turbo SE MR images. The gadolinium set included unenhanced T1- and T2-weighted images and dynamic gadolinium-enhanced three-dimensional turbo field-echo MR images. In receiver operating characteristic (ROC) curve analysis, the sensitivity and accuracy of the sequences were compared in regard to the detection of all, small, and large HCCs.

RESULTS

Imaging performance was different with gadolinium- and ferumoxides-enhanced images in the detection of small and large HCCs. For detection of small HCCs, the sensitivity and accuracy with unenhanced and gadolinium-enhanced imaging (gadolinium set) were significantly (P =.017) superior to those with unenhanced and ferumoxides-enhanced imaging (ferumoxides set). The area under the composite ROC curves, or A(z), for the gadolinium set and the ferumoxides set was 0.97 and 0.81, respectively. For large HCC, the ferumoxides set was superior compared with the gadolinium set, but this difference was not statistically significant. Analysis of all HCCs demonstrated no significant differences for gadolinium- and ferumoxides-enhanced imaging.

CONCLUSION

For the detection of early HCC, gadolinium-enhanced MR imaging is preferred to ferumoxides-enhanced MR imaging because the former demonstrated significantly greater accuracy in the detection of small HCCs.

Detection of malignant hepatic tumors: comparison of gadolinium-and ferumoxide-enhanced MR imaging

OBJECTIVE

The purpose of our study was to compare how well gadolinium-enhanced and ferumoxide-enhanced MR imaging reveal malignant hepatic tumors.

SUBJECTS AND METHODS

Both gadolinium-enhanced and ferumoxide-enhanced MR imaging were separately performed in 53 patients with a total of 87 malignant hepatic tumors (57 hepatocellular carcinomas, 28 metastases, two cholangiocarcinomas). Thirty-one of the 53 patients had hepatic cirrhosis. Images were reviewed by three independent off-site observers. Observer performance was evaluated by means of sensitivity, specificity, and receiver operating characteristic curve analyses.

RESULTS

Gadolinium-enhanced MR imaging outperformed ferumoxide-enhanced MR imaging in sensitivity (81% versus 62%, p < 0.01) for malignant-tumor detection. Specificity was comparable (94%) between the two types of MR imaging. Area under receiver operating characteristic curve (A(z)) value was significantly higher with gadolinium-enhanced MR imaging than with ferumoxide-enhanced MR imaging in patients overall (A(z) = 0.896 versus 0.805, p < 0.001), in patients with cirrhosis (A(z) = 0.907 versus 0.807, p < 0.001), and in patients without cirrhosis (A(z) = 0.899 versus 0.834, p < 0.01). The superiority was enhanced in the subset of patients with cirrhosis.

CONCLUSION

Gadolinium-enhanced MR imaging outperforms ferumoxide-enhanced MR imaging in revealing malignant hepatic tumors. Gadolinium-enhanced MR imaging is recommended, particularly for patients with cirrhosis.

Small nodule detection in cirrhotic livers: evaluation with US, spiral CT, and MRI and correlation with pathologic examination of explanted liver

PURPOSE

The purpose of this work was to evaluate the detection and characterization of nodules > or = 8 mm and small hepatocellular carcinomas (HCCs) in liver cirrhosis.

METHOD

Pathologic examination and results of US, helical CT, and dynamic MRI with gadolinium were compared after orthotopic liver transplantation (OLT) of 43 cirrhotic patients. Nodules were classified as macroregenerative nodules (MRNs), borderline nodules (BNs), and HCC.

RESULTS

Pathologic examination classified 69 nodules: 50 MRNs, 6 BNs, and 13 HCCs. Sensitivities of MRN, BN, and HCC detection were, respectively, for US imaging 2% (1/50), 33.3% (2/6), and 46.2% (6/13); for helical CT 2% (1/50), 50% (3/6), and 53.8% (7/13); and for MRI 42% (21/50), 50% (3/6), and 76.9% (10/13). MRI detected 21 MRNs. They presented on T1/T2-weighted images as hyperintense/hypointense (n = 8), hyperintense/isointense (n = 7), hypointense/hypointense (n = 4), hypointense/isointense (n = 1), and hypointense depicted only on echo planar imaging (n = 1). The three detected BNs were hyperintense/hypointense nodules. The 10 detected HCCs appeared hyperintense/isointense (n = 7), hyperintense/hypointense (n = 2), and hypointense/isointense (n = 1). None of the MRNs but eight HCCs and one BN were enhanced after gadolinium injection.

CONCLUSION

Contrast-enhanced MRI is the most sensitive technique for detecting liver nodules. No MR signal intensity pattern characteristic of small HCCs enables differentiation from benign nodules, however. Gadolinium enhancement is the most sensitive and specific characteristic of HCC.

Dual contrast enhanced magnetic resonance imaging of the liver with superparamagnetic iron oxide followed by gadolinium for lesion detection and characterization

AIM

Iron oxide contrast agents are useful for lesion detection, and extracellular gadolinium chelates are advocated for lesion characterization. We undertook a study to determine if dual contrast enhanced liver imaging with sequential use of ferumoxides particles and gadolinium (Gd)-DTPA can be performed in the same imaging protocol.

MATERIALS AND METHODS

Sixteen patients underwent dual contrast magnetic resonance imaging (MRI) of the liver for evaluation of known/suspected focal lesions which included, metastases (n = 5), hepatocellular carcinoma (HCC;n = 3), cholangiocharcinoma(n = 1) and focal nodular hyperplasia (FNH;n = 3). Pre- and post-iron oxide T1-weighted gradient recalled echo (GRE) and T2-weighted fast spin echo (FSE) sequences were obtained, followed by post-Gd-DTPA (0.1 mmol/kg) multi-phase dynamic T1-weighted out-of-phase GRE imaging. Images were analysed in a blinded fashion by three experts using a three-point scoring system for lesion conspicuity on pre- and post-iron oxide T1 images as well as for reader's confidence in characterizing liver lesions on post Gd-DTPA T1 images.

RESULTS

No statistically significant difference in lesion conspicuity was observed on pre- and post-iron oxide T1-GRE images in this small study cohort. The presence of iron oxide did not appreciably diminish image quality of post-gadolinium sequences and did not prevent characterization of liver lesions.

CONCLUSION

Our results suggest that characterization of focal liver lesion with Gd-enhanced liver MRI is still possible following iron oxide enhanced imaging.Kubaska, S.et al. (2001). Clinical Radiology, 56, 410-415

Malignant hepatic tumor detection with ferumoxides-enhanced MR imaging with a 1.5-T system: comparison of four imaging pulse sequences

The purpose of our study was to compare observer performance in the detection of malignant hepatic tumors with ferumoxides-enhanced magnetic resonance (MR) images obtained with proton density-weighted spin-echo (SE), T2-weighted fast SE, T2*-weighted gradient-recalled-echo (GRE), and proton density-weighted echo-planar (EP) sequences. Ferumoxides-enhanced MR images obtained with the four sequences in 50 patients with 92 solid malignant and 64 nonsolid benign lesions were retrospectively analyzed. Image review was conducted on a segment-by-segment basis; a total of 397 liver segments was reviewed separately for solid and nonsolid lesions by three independent readers. Observer performance was evaluated with receiver operating characteristic analysis. Lesion-to-liver contrast-to-noise ratio was higher with SE and EP than with GRE and fast SE images for solid lesions (P < 0.05), and higher with fast SE and SE than with GRE images for nonsolid lesions (P < 0.01). Proton density-weighted SE and T2-weighted fast-SE images were superior to T2*-weighted GRE and proton density-weighted EP images for detection of malignant hepatic tumors. T2-weighted fast SE images were the best for detection of nonsolid lesions. T2-weighted fast SE images that were comparable to proton density-weighted SE images for solid tumor detection, that were the best for nonsolid lesion detection, and that had an acquisition time of one third to half of that of SE imaging may be able to replace SE images for ferumoxides-enhanced liver imaging.

Correlation of three-dimensional gradient echo dynamic MR imaging with CT during hepatic arteriography in patients with hypervascular hepatocellular carcinomas: preliminary clinical experience

The purpose of this study is to elucidate the usefulness of dynamic MR study of the whole liver using 3DFISP with double dose gadolinium (Gd) enhancement in detecting enhancing lesions in 20 patients. Twenty patients with hepatocellular carcinoma (HCC) underwent 3DFISP dynamic study with double dose Gd. The demonstration of enhancing hypervascular lesions regardless of etiology was evaluated on a segment-by-segment basis with receiver operating characteristic (ROC) analysis, using findings on CT during hepatic arteriography as a gold standard. Diagnostic accuracy of 3DFISP in the detection of HCC was also evaluated. As to the demonstration of enhancing lesions, the Az value of the ROC curve was 88%. The detection rate of HCC with 3DFISP was 98%. 57% of enhancing pseudolesions were not detected on 3DFISP. We concluded that Dynamic MR study of the whole liver using 3DFISP with double dose Gd enhancement is a useful method to demonstrate hypervascular HCC.

Pseudothrombosis in the portal venous system: a potential pitfall with gadolinium-enhanced dynamic gradient-recalled echo imaging of the liver

Gadolinium-enhanced dynamic magnetic resonance (MR) images in 90 patients were reviewed to assess the artifacts mimicking portal venous thrombosis. The incidence of definite signal-intensity decrease mimicking pathologic condition was higher (P < 0.01) in the right (8%) and left (9%) portal vein branches and portal trunk (6%) than in the splenic (0%) or superior mesenteric (1%) vein with equilibrium-phase images. Radiologists should remember that dynamic MR images occasionally show signal-intensity decrease mimicking portal venous thrombosis due to flow artifact.

Improved tissue characterization of focal liver lesions with ferumoxide-enhanced T1 and T2-weighted MR imaging

The purpose of our study was to evaluate the potential value of ferumoxide-enhanced T1-weighted magnetic resonance (MR) imaging for tissue characterization of focal liver lesions when combined with T2-weighted sequences. Images were acquired within 30 minutes after the end of ferumoxide administration, when ferrite particles were not totally cleared from the intravascular compartment. Thirty-eight patients with 47 focal liver lesions underwent T1-weighted gradient-echo (TR/TE 150/4.1 msec) and T2-weighted fast spin-echo (3180-8638/90 msec) MR imaging at 1.5 T before and after intravenous administration of ferumoxides (10 micromol/kg body weight). A qualitative and quantitative analysis was performed. During the early phase after infusion of ferumoxide, blood vessels showed hypersignal intensity on T1-weighted fast low-angle shot (FLASH) images, while liver signal decreased. Hemangiomas showed both homogeneous and inhomogeneous enhancement patterns, and liver metastasis most typically showed ring enhancement. Hypervascular tumors (hepatocellular carcinomas and focal nodular hyperplasias) showed a slight degree of homogeneous enhancement. Quantitatively, the degree of enhancement and lesion-to-liver contrast on ferumoxide-enhanced images were significantly different among these tumors. Our results demonstrate that distinct enhancement patterns obtained on ferumoxide-enhanced T1-weighted MR imaging improve tissue characterization of focal liver lesions when combined with T2-weighted images.

Preoperative detection of malignant hepatic tumors: comparison of combined methods of MR imaging with combined methods of CT

OBJECTIVE

We compared radiologists' performance on combined unenhanced, gadolinium-enhanced, and ferumoxides-enhanced MR imaging with their performance on helical CT during arterial portography (CTAP) and biphasic CT during hepatic arteriography (CTHA) for the preoperative detection of malignant hepatic tumors.

SUBJECTS AND METHODS

MR images and CT scans obtained in 33 patients were retrospectively analyzed. Images of the liver were reviewed on a segment-by-segment basis; a total of 261 segments with 39 hepatocellular carcinomas and 21 metastases were independently reviewed by three radiologists who were invited from outside institutions. Unenhanced and gadolinium-enhanced MR images were reviewed first, then ferumoxides-enhanced MR images were added for combined review. CTAP images and biphasic CTHA images were reviewed together.

RESULTS

Sensitivity for the detection of hepatic tumors was analogous for combined unenhanced, gadolinium-enhanced, and ferumoxides-enhanced MR images (86%) and for combined CTAP images and biphasic CTHA images (87%). Specificity was higher with MR images (95%, p < 0.01) than with CT images (91%). Radiologists' performances were improved (Az = 0.962, p = 0.0502) by combining ferumoxides-enhanced MR images with unenhanced and gadolinium-enhanced MR images (Az = 0.950), and were analogous for combined unenhanced, gadolinium-enhanced, and ferumoxides-enhanced MR images and for combined CTAP images and biphasic CTHA images (Az = 0.959).

CONCLUSION

Radiologists' performances on combined unenhanced, gadolinium-enhanced, and ferumoxides-enhanced MR imaging compared with their performances on combined helical CTAP and biphasic CTHA are analogous for the preoperative detection of malignant hepatic tumors. Such a dedicated combination of MR imaging may obviate the need for more invasive angiographically assisted helical CT for the preoperative detection of malignant hepatic tumors.

Imaging of atypical hemangiomas of the liver with pathologic correlation

Compared with the imaging features of typical hepatic hemangiomas, the imaging features of atypical hepatic hemangiomas have not been well studied or well described. Knowledge of the entire spectrum of atypical hepatic hemangiomas is important and can help one avoid most diagnostic errors. A frequent type of atypical hepatic hemangioma is a lesion with an echoic border at ultrasonography. Less frequent types are large, heterogeneous hemangiomas; rapidly filling hemangiomas; calcified hemangiomas; hyalinized hemangiomas; cystic or multilocular hemangiomas; hemangiomas with fluid-fluid levels; and pedunculated hemangiomas. Adjacent abnormalities consist of arterial-portal venous shunt, capsular retraction, and surrounding nodular hyperplasia; hemangiomas can also develop in cases of fatty liver infiltration. Associated lesions include multiple hemangiomas, hemangiomatosis, focal nodular hyperplasia, and angiosarcoma. Types of atypical evolution are hemangiomas enlarging over time and hemangiomas appearing during pregnancy. Complications consist of inflammation, Kasabach-Merritt syndrome, intratumoral hemorrhage, hemoperitoneum, volvulus, and compression of adjacent structures. In some cases, such as large heterogeneous hemangiomas, calcified hemangiomas, pedunculated hemangiomas, or hemangiomas developing in diffuse fatty liver, a specific diagnosis can be established with imaging, especially magnetic resonance imaging. However, in other atypical cases, the diagnosis will remain uncertain at imaging, and these cases will require histopathologic examination.